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MuBACKGROUND Despite advances in hospital management in recent years, it is not clear whether mortality after acute
pulmonary embolism (PE) has decreased over time.
OBJECTIVES This study describes the trends in the management and outcomes of acute symptomatic PE.
METHODS We identiﬁed adults with acute PE enrolled in the registry between 2001 and 2013. We assessed temporal
trends in length of hospital stay and use of pharmacological and interventional therapies. Using multivariable regression,
we examined temporal trends in risk-adjusted rates of all-cause and PE-related death to 30 days after diagnosis.
RESULTS Among 23,858 patients with PE, mean length of stay decreased from 13.6 to 9.3 days over time (32% relative
reduction, p < 0.001). For initial treatment, use of low-molecular-weight heparin increased from 77% to 84%, whereas
the use of unfractionated heparin decreased from 22% to 8.4% (p < 0.001 for trend for all comparisons). Thrombolytic
therapy use increased from 0.7% to 1.0% (p ¼ 0.07 for trend) and surgical embolectomy use doubled from 0.3% to
0.6% (p < 0.01 for trend). Risk-adjusted rates of all-cause mortality decreased from 6.6% in the ﬁrst period (2001 to
2005) to 4.9% in the last period (2010 to 2013) (p ¼ 0.02 for trend). Rates of PE-related mortality decreased over time,
with a risk-adjusted rate of 3.3% in 2001 to 2005 and 1.8% in 2010 to 2013 (p < 0.01 for trend).
CONCLUSIONS In a large international registry of patients with PE, improvements in length of stay and changes in the
initial treatment were accompanied by a reduction in short-term all-cause and PE-speciﬁc mortality.
(J Am Coll Cardiol 2016;67:162–70) © 2016 by the American College of Cardiology Foundation.P ulmonary embolism (PE) remains a worldwidemajor health issue (1). PE is the most commoncause of vascular death after myocardial
infarction and stroke, and it is the leading prevent-
able cause of death in hospital patients (2).
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163determine the extent to which evidence is applied in
practice, whether this is changing over time, and
whether such changes are associated with improved
outcomes.SEE PAGE 171
PE = pulmonary embolism
sPESI = simpliﬁed Pulmonary
Embolism Severity Index
V/Q = ventilation/perfusion
VTE = venous
thromboembolismThe ongoing, multicenter, international, prospec-
tive RIETE (Registro Informatizado de la Enfermedad
TromboEmbólica) Registry includes consecutive pa-
tients with symptomatic, objectively conﬁrmed,
acute venous thromboembolism (VTE) (11–13). Since
its launch in 2001, investigators have enrolled a total
of 50,782 patients in RIETE, which has a sufﬁciently
large sample size (25,456 patients with PE) and study
duration (13 years of recruitment) to deﬁne changes
in management and outcome. We hypothesized that
temporal changes in hospital management of patients
with acute PE (i.e., length of hospital stay, use of
evidence-based treatments) would be signiﬁcantly
associated with a reduction in mortality, independent
of the risk status of the study population on presen-
tation to hospital.
METHODS
STUDY DESIGN. We conducted a retrospective cohort
study that used prospectively collected data from
patients enrolled in the RIETE registry. All patients
provided written or oral consent for participation in
the registry in accordance with local ethics committee
requirements.
DATA SOURCE. Previous publications have described
the design and conduct of the RIETE registry (14,15).
Brieﬂy, at each participating RIETE site, investigatorsSpain (through an unrestricted educational grant) and Bayer Pharma AG. Bay
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positive contrast-enhanced, PE-protocol, he-
lical chest computed tomography (CT) [single
or multidetector CT] for PE (17); or lower
limb venous compression ultrasonography
positive for proximal deep vein thrombosis
(18).
DATA QUALITY CONTROL. To ensure the validity of
the information entered into the database, 1 of the
specially trained monitors visited each participating
hospital and compared information in 25 to 50
randomly chosen patient records with the informa-
tion entered into the RIETE database. For data quality
assessment, monitors assessed 4,100 random records
from all participating hospitals that included
1.23 million measurements. These data showed a 95%
overall agreement between the registered informa-
tion and patient records. RIETE also used electronic
data monitoring to detect inconsistencies or errors
and attempted to resolve discrepancies by contacting
the local coordinators.
ELIGIBILITY. This study included patients that
enrolled in RIETE and had a diagnosis of acute
symptomatic PE from January 1, 2001 through
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and patients at hospitals with low case volumes
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FIGURE 1 STROBE Study Cohort Flow Diagram
50,782 patients with acute VTE
were enrolled in RIETE
25,326 were excluded with DVT
without symptomatic PE
25,456 patients with acute symptomatic PE
at 272 hospitals were identified
269 were excluded at 21 hospitals
with <3 yrs of data submission
25,187 had a PE at a hospital
with ≥3 yrs of data
1,329 were excluded at 115
hospitals with volume <30
23,858 patients at 136 hospitals
constituted the final study population
DVT ¼ deep venous thrombosis; PE ¼ pulmonary embolism; RIETE ¼ Registro Informatizado de la Enfermedad TromboEmbólica;
STROBE ¼ STrengthening the Reporting of OBservational studies in Epidemiology; VTE ¼ venous thromboembolism.
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164VARIABLES. Patients enrolled in RIETE had data
collected from around the time of VTE diagnosis that
included but were not limited to: age; sex; body
weight; presence of coexisting conditions such as
chronic heart or lung disease; recent (<30 days prior
to VTE) major bleeding; presence of risk factors for PE
including active cancer (deﬁned as newly diagnosed
cancer or cancer undergoing treatment [i.e., surgery,
chemotherapy, radiotherapy, hormonal, or support
therapy]); recent immobility (deﬁned as nonsurgical
patients assigned to bed rest with bathroom privi-
leges for $4 days in the 2 months prior to VTE diag-
nosis); surgery (deﬁned as those who had undergone
major surgery in the 2 months prior to VTE); clinical
signs and symptoms on admission, including heart
rate, systolic blood pressure and arterial oxyhemo-
globin saturation; and laboratory results at hospital
admission that included hemoglobin, platelet count,
and serum creatinine.
STUDY OUTCOMES. The primary outcome was
30-day all-cause mortality (deﬁned as death from any
cause 30 days after the diagnosis of PE). To better
understand the association between speciﬁc phases
of treatment and mortality, we examined rates of
death from any cause within the 7 days following thediagnosis of PE. We also examined temporal trends in
PE-related mortality through 7 and 30 days after
diagnosis. The RIETE investigators used medical
record review to assess vital status. For patients that
died, further medical record review, and proxy
interviews when necessary, assisted with deter-
mining date and cause of death. For deaths conﬁrmed
by autopsy or those following a clinically severe PE,
either initially or shortly after an objectively
conﬁrmed recurrent event, in the absence of any
alternative diagnosis, the investigators were instruc-
ted to judge death as due to fatal PE. We chose 7- and
30-day mortality assessment periods because they
likely reﬂected variations related to changes in length
of stay and evidence-based treatments and because
they are standard measurements of quality of care
(19). In addition, we examined rates of nonfatal VTE
recurrences, and fatal and nonfatal bleeding events
within 30 days following the diagnosis of PE.
STATISTICAL ANALYSIS. To evaluate changes in
baseline characteristics by calendar period, we used
the Mantel-Haenszel test of trend for categorical
variables and linear regression for continuous vari-
ables. We used the Cochran-Armitage trend test to
determine the statistical signiﬁcance of changes over
TABLE 1 Trends in Baseline Characteristics in Patients With Acute Pulmonary Embolism*
Year Group
p Value
for Trend
2001–2005
(n ¼ 7,323)
2006–2009
(n ¼ 8,644)
2010–2013
(n ¼ 7,891)
Clinical characteristics
Age, yrs 68.5  16.0 67.5  17.1 67.3  17.0 <0.001
Age >80 yrs 1,670 (22.8) 2,035 (23.5) 1,897 (24.0) 0.07
Male 3,374 (46.1) 3,969 (45.9) 3,655 (46.3) 0.59
Weight, kg 73.8  14.5 74.9  15.8 76.0  16.1 <0.001
Risk factors for VTE
History of VTE 1,139 (15.6) 1,236 (14.3) 1,188 (15.1) 0.10
Cancer† 1,552 (21.2) 2,030 (23.5) 1,785 (22.6) <0.01
Recent surgery‡ 953 (13.0) 1,015 (11.7) 899 (11.4) <0.01
Immobilization for $4 days§ 1,892 (25.8) 2,035 (23.5) 1,668 (21.1) <0.001
Comorbid diseases
Chronic lung disease 1,016 (13.9) 1,095 (12.7) 1,290 (16.3) <0.001
Chronic heart disease 630 (8.6) 711 (8.2) 836 (10.6) <0.001
Recent major bleeding 176 (2.4) 178 (2.1) 183 (2.3) 0.84
Clinical symptoms and signs
at presentation
Pulse, beats/min 94.1  19.9 93.3  19.9 91.5  20.2 <0.001
Pulse $110 beats/min 1,629 (22.7) 1,763 (21.0) 1,475 (19.4) <0.001
Systolic blood pressure,
mm Hg
130.1  24.9 129.3  24.3 129.1  23.9 <0.001
Systolic blood pressure
<100 mm Hg
533 (7.3) 683 (7.9) 711 (9.0) <0.001
Arterial oxyhemoglobin
saturation (SaO2) <90%
1,822 (31.1) 1,689 (29.0) 1,322 (29.9) 0.29
sPESI (21)
Low risk 1,559 (27.1) 1,660 (28.8) 1,169 (26.8) 0.66
High risk 4,203 (72.9) 4,110 (71.2) 3,185 (73.2) 0.66
Laboratory ﬁndings
Abnormal creatinine levels
(>2 mg/dl)
1,283 (17.6) 1,541 (18.3) 1,519 (19.8) <0.01
Hemoglobin, g/dl 13.04  2.0 12.99  2.0 12.97  2.0 <0.01
Values are mean  SD or n (%). *For illustrative purposes, trends in baseline characteristics are presented as 3
time periods: 2001–2005, 2006–2009, and 2010–2013. The p value for trend is for temporal changes in these
characteristics by calendar year. †Active or under treatment in the last year. ‡In the previous month. §Immo-
bilized patients were deﬁned as nonsurgical patients who had been immobilized (i.e., total bed rest with bath-
room privileges) for $4 days in the month prior to PE diagnosis.
sPESI ¼ simpliﬁed Pulmonary Embolism Severity Index; VTE ¼ venous thromboembolism.
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165time in the binary outcomes and the Cuzick
nonparametric test in the continuous outcomes.
To assess mortality rates over time, we constructed
multivariable regression models for the overall
cohort. We adjusted generalized linear models for
age, sex, coexisting conditions (i.e., cancer, immobi-
lization, chronic lung disease, and chronic heart dis-
ease), severity of PE (i.e., heart rate, systolic blood
pressure, arterial oxyhemoglobin saturation, simpli-
ﬁed Pulmonary Embolism Severity Index [sPESI]),
and laboratory results (i.e., creatinine levels, hemo-
globin levels) at hospital admission. These models
accounted for clustering of patients within hospitals.
We included the independent variable, calendar
period, a categorical variable with 2001 to 2005 as the
reference period. We multiplied the adjusted rate
ratio for each period by the observed mortality rate
for the reference period to obtain risk-adjusted mor-
tality rates for the study period. These rates repre-
sented the estimated mortality for each period if the
patient case mix was identical to that in the reference
period.
To conﬁrm that any mortality trends were inde-
pendent of the duration of hospital participation in
the registry, we adjusted for the number of years of
hospital participation for each patient. We also
examined whether mortality trends differed by diag-
nostic test (CT vs. V/Q scan) and age group ($65 years
vs. <65 years) by including an interaction term with
calendar period in the model. To exclude the possi-
bility that our ﬁndings were due to enrollment of
better-performing hospitals over time, we performed
these analyses only for patients at hospitals
with $5 years of registry participation. Last, we
repeated analyses for the subgroup of patients with
acute PE that had hypotension (i.e., systolic blood
pressure <90 mm Hg).
Data were complete for all covariates and outcomes
except heart rate (3.0% missing), arterial oxyhemo-
globin saturation (32% missing), and creatinine levels
(2.0% missing) at the time of PE diagnosis. Missing
patient-level covariates were assumed to be missing
at random and were imputed using multiple impu-
tation (20).
We conducted statistical analyses with STATA
version 13.1 (STATA Corp, College Station, Texas). All
hypothesis tests were 2-sided, with a signiﬁcance
level of 0.05.
The study’s sponsor had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had
full access to all the data in the study and had ﬁnal
responsibility for the decision to submit for
publication.RESULTS
STUDY POPULATION. We identiﬁed 25,456 adults at
272 hospitals participating in the RIETE registry that
had a diagnosis of acute symptomatic PE during the
time period of January 1, 2001, through December 31,
2013 (Figure 1). We excluded 269 patients at 21 hos-
pitals with <3 years of data submission and 1,329
patients at 115 hospitals with low case volumes
(<30 PEs). The ﬁnal study sample included 23,858
patients from 136 hospitals.
PATIENT CHARACTERISTICS. There was initially an
increase in number of sites participating in RIETE,
from 92 sites providing 7,323 patients in the ﬁrst
period from 2001 to 2005 to a fairly stable number of
CENTRAL ILLUSTRATION Acute PE Mortality in the RIETE Registry: Signiﬁcant Reductions in Mortality Over Time
Jiménez, D. et al. J Am Coll Cardiol. 2016; 67(2):162–70.
The RIETE (Registro Informatizado de la Enfermedad TromboEmbólica) registry showed signiﬁcant temporal changes in the management of patients with pulmonary
embolism (PE) (A and B) that were consistent with trial evidence and national and international guidelines. Decreases in length of hospital stay (C) and in the rates of
short-term all-cause and PE-speciﬁc mortality (D) accompanied these changes in practice. (A) Anticoagulant use (unadjusted p < 0.001 for trend for all comparisons).
(B) The use of other pharmacological and interventional therapies (unadjusted p ¼ 0.07 for trend for use of thrombolytics; unadjusted p < 0.01 for trend for use of
surgical embolectomy; unadjusted p ¼ 0.90 for trend for use of inferior vena cava ﬁlter). (C) Length of stay (unadjusted p < 0.001 for trend). (D) Unadjusted p < 0.01
for trend for 30-day all-cause mortality curve. Unadjusted p < 0.01 for trend for 30-day pulmonary embolism (PE)-related mortality curve. LMWH ¼ low-molecular-
weight heparin; UFH ¼ unfractionated heparin.
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166approximately 120 sites with 8,000 patients in the 2
subsequent 4-year periods.
During the study period, the proportion of patients
who had PE assessment with CT increased from 47% to
90%, whereas the proportion of patients who were
assessed with V/Q scan decreased from 58% to 11%(p< 0.001 for trends). Table 1 shows temporal trends in
patient characteristics, grouped into 3 time periods.
During the study period, there was a calendar-year
trend for younger age (68 to 66 years), whereas the
proportion of women did not vary (53% in 2001 to 50%
in 2013; p ¼ 0.59). The prevalence of cancer, chronic
TABLE 2 Observed Rates of Mortality and Nonfatal Outcomes by Year Group
2001–2005 2006–2009 2010–2013
30-day all-cause mortality 489/7,323 (6.7) 541/8,644 (6.2) 388/7,891 (4.9)
7-day all-cause mortality 220/7,323 (3.0) 244/8,644 (2.8) 145/7,891 (1.8)
30-day PE-related mortality 258/7,323 (3.5) 244/8,644 (2.8) 143/7,891 (1.8)
7-day PE-related mortality 176/7,323 (2.4) 173/8,644 (2.0) 89/7,891 (1.1)
Nonfatal complications
30-day VTE recurrences 82/7,323 (1.1) 52/8,644 (0.6) 52/7,891 (0.6)
30-day major bleeding 299/7,323 (4.1) 225/8,644 (2.6) 250/7,891 (3.2)
30-day fatal bleeding 30/7,323 (0.4) 33/8,644 (0.4) 19/7,891 (0.2)
Values are n/N (%).
PE ¼ pulmonary embolism; VTE ¼ venous thromboembolism.
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167lung disease, and chronic heart failure increased over
time. Alternatively, the study showed decreases in a
history of immobility (27% to 21%) and a history of
surgery (14% to 12%) over time. A history of recent
bleeding did not signiﬁcantly change over time (2.6%
in 2001 to 3.1% in 2013; p ¼ 0.84 for trends).
During the study period, the proportion of high-
risk patients according to the sPESI (21) did not vary
(72% in 2001 to 74% in 2013; p ¼ 0.66 for trends)
(Table 1), although the sPESI mean scores increased
from 1.26 in 2001 to 1.31 in 2013 (p < 0.001 for trends).
Regarding time trends for signs of clinical PE severity,
mean heart rate and systolic blood pressure signiﬁ-
cantly decreased (p < 0.001 for trend for all compar-
isons), but arterial oxyhemoglobin saturation did not
vary (91%). The proportion of patients with elevated
creatinine levels (i.e., creatinine >2 mg/dl) increased
from 18% (95% conﬁdence interval [CI]: 16% to 21%)
to 20% (95% CI: 17% to 22%) (p < 0.01), whereas mean
hemoglobin levels signiﬁcantly decreased over time
(p < 0.01 for trends) (Table 1).
TEMPORAL TRENDS IN LENGTH OF HOSPITAL STAY
AND PHARMACOLOGICAL MANAGEMENT. During
the 13-year study period, mean length of hospital stay
decreased from 13.6 days (95% CI: 11.2 to 15.9 days) to
9.3 days (95% CI: 8.8 to 9.7 days) (32% relative
reduction; p < 0.001) (Central Illustration). A total of
0.03% (2 of 7,323; 0.03%; 95% CI: 0.0% to 0.1%) of
patients were managed as outpatients between 2001
and 2005; 0.6% (52 of 8,644; 0.6%; 95% CI: 0.4% to
0.8%) between 2006 and 2009; and 1.7% (134 of 7,891;
95% CI: 1.4% to 2.0%) between 2010 and 2013.
Regarding in-hospital treatments known to inﬂuence
outcomes, the use of low-molecular-weight heparins
(77% in 2001 to 84% in 2013) and direct oral antico-
agulants (0% in 2001 to 2.2% in 2013) showed an in-
crease, whereas the use of unfractionated heparin
decreased from 22% to 8.4% over the study period
(p < 0.001 for trend for all comparisons). Thrombol-
ysis showed an increase from 0.7% to 1.0% (p ¼ 0.07
for trends), and surgical embolectomy increased from
0.3% to 0.6% (p < 0.01 for trends), whereas ﬁlter
insertion showed a nonstatistically signiﬁcant
downward trend (3.4% in 2001 to 2.3% in 2013; p ¼
0.90) (Central Illustration).
TEMPORAL TRENDS IN MORTALITY. The entire
cohort had a 30-day all-cause mortality rate of 5.9%
(n ¼ 1,418 of 23,858). There was a signiﬁcant trend to-
ward decreased mortality during the study period for
all study patients (Central Illustration, Table 2). After
adjustment for temporal trends in patient character-
istics around the time of PE diagnosis, overall mortal-
ity decreased from 6.6% from 2001 to 2005 to 4.9%from 2010 to 2013 (adjusted rate ratio per period:
0.84; 95% CI: 0.73 to 0.97; p ¼ 0.02 for trend) (Tables 3
and 4). The temporal trends in mortality were similar
according to diagnostic procedure (CT vs. V/Q scan)
and age group ($65 years vs.<65 years) (p> 0.10 for all
interactions). For analyses restricted to the 110 hospi-
tals (21,947 patients) that participated in the RIETE
Registry for at least 5 years, the trends remained un-
changed (Table 5). Only 778 of 23,858 (3.3%; 95% CI:
3.0% to 3.5%) patients with acute PE had hypotension.
Among hypotensive patients, the 30-day all-cause
mortality decreased from 15.4% in the ﬁrst period of
2001 to 2005 to 13.4% in 2006 to 2009 and 12.1% in the
last period of 2010 to 2013 (p ¼ 0.30 for trend).
The entire cohort had a 7-day all-cause mortality
rate of 2.6% (609 of 23,858 patients). Rates of 7-day
all-cause mortality decreased over time, with a risk-
adjusted rate of 2.9% in 2001 to 2005 and 1.9% in
2010 to 2013 (adjusted rate ratio per period: 0.81; 95%
CI: 0.67 to 0.98; p ¼ 0.03 for trend) (Table 3). Among
hypotensive patients, the 7-day all-cause mortality
decreased from 26 of 234 (11.1%) in 2001 to 2005 to 16
of 239 (6.7%) in 2010 to 2013 (p ¼ 0.08 for trend).
SECONDARY OUTCOMES. After adjustment, 30-day
PE-related mortality signiﬁcantly decreased from
3.3% in 2001 to 2005 to 1.8% in 2010 to 2013 (adjusted
rate ratio per period: 0.73; 95% CI: 0.60 to 0.89;
p < 0.01 for trend), whereas 7-day PE-related mor-
tality decreased from 2.2% in 2001 to 2005 to 1.1% in
2010 to 2013 (adjusted rate ratio per period: 0.72;
95% CI: 0.58 to 0.90; p < 0.01 for trend).
Rates of nonfatal PE recurrence decreased over
time, with a risk-adjusted rate of 1.1% in 2001 to 2005
and 0.6% in 2010 to 2013 (adjusted rate ratio per
period: 0.72; 95% CI: 0.58 to 0.91; p < 0.01 for trend)
(Table 3). Nonfatal major bleeding decreased over
time (risk-adjusted rate: 4.0% in 2001 to 2005 and
3.1% in 2010 to 2013; adjusted rate ratio per year:
0.89; 95% CI: 0.77 to 1.03; p ¼ 0.11 for trend). For
TABLE 3 Trends in Mortality and Nonfatal Outcomes
Risk-Adjusted Rates (%)*
Adjusted
Rate Ratio
Per Period
(95% CI)†
p Value
for Trend†2001–2005 2006–2009 2010–2013
30-day all-cause mortality 6.6 6.1 4.9 0.84 (0.73–0.97) 0.02
7-day all-cause mortality 2.9 2.7 1.9 0.81 (0.67–0.98) 0.03
30-day PE-related mortality 3.3 2.7 1.8 0.73 (0.60–0.89) <0.01
7-day PE-related mortality 2.2 1.9 1.1 0.72 (0.58–0.90) <0.01
Nonfatal complications
30-day VTE recurrences 1.1 0.6 0.6 0.72 (0.58–0.91) <0.01
30-day major bleeding 4.0 2.7 3.1 0.89 (0.77–1.03) 0.11
*Risk-adjusted rates of all-cause mortality, PE-related mortality, and nonfatal complications for each calendar
period are reported for the overall cohort. Rates were adjusted for temporal changes in patient and hospital
characteristics (see Table 4 for all model covariates). †Adjusted risk ratios and p values for trend were determined
with a model evaluating calendar period as a continuous variable.
CI ¼ conﬁdence interval; other abbreviations as in Table 2.
TABLE 4 Multivariable Model of Predictors of 30-Day Mortality*
Adjusted
Odds Ratio 95% CI p Value
Calendar year (per 1 yr) 0.96 0.93–0.99 0.02
Age (per 1 yr) 1.03 1.02–1.04 <0.001
Sex (female vs. male) 0.74 0.65–0.85 <0.001
Weight (per 1 kg) 0.98 0.97–0.98 <0.001
History of VTE 0.62 0.51–0.75 <0.001
Cancer† 3.33 2.85–3.88 <0.001
Recent surgery‡ 0.56 0.44–0.71 <0.001
Immobilization for $4 days§ 2.09 1.81–2.41 <0.001
Chronic lung disease 1.04 0.75–1.44 0.80
Chronic heart disease 1.35 1.01–1.80 0.04
Recent major bleeding 1.29 0.94–1.77 0.12
Pulse (per 1 beat/min) 1.01 1.01–1.02 <0.001
Systolic blood pressure
(per mm Hg)
0.99 0.985–0.993 <0.001
Arterial oxyhemoglobin
saturation (SaO2) (per 1%)
0.97 0.96–0.97 <0.001
Abnormal creatinine levels
(>2 mg/dl)
1.57 1.35–1.83 <0.001
Hemoglobin (per 1 g/dl) 0.87 0.84–0.91 <0.001
*Adjusted odds ratio, 95% conﬁdence intervals, and p values are provided for all
model covariates included in the multivariable model for 30-day mortality in the
overall cohort. †Active or under treatment in the last year. ‡In the previous month.
§Immobilized patients were deﬁned as nonsurgical patients who had been
immobilized (i.e., total bed rest with bathroom privileges) for $4 days in the
month prior to PE diagnosis.
Abbreviations as in Tables 2 and 3.
TABLE 5 Trends in M
at Hospitals Participa
30-day all-cause
mortality
7-day all-cause
mortality
30-day PE-related
mortality
7-day PE-related
mortality
Nonfatal complications
30-day VTE
recurrences
30-day major
bleeding
*Risk-adjusted rates of all-
period are reported for th
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16830-day fatal bleeding, data were too sparse to show
trends (Table 2).
DISCUSSION
These data, from the largest multinational, observa-
tional cohort study of patients with an acute PE,
demonstrated evidence of a recent temporal change
in practice for both length of hospital stay and phar-
macological and interventional treatments of acute
PE. Decreases in the rates of short-term all-cause and
PE-speciﬁc mortality accompanied these changes in
practice. The risk status of patients at presentation
with PE did not improve over the course of the pre-
sent study, so it may be plausible that the changes in
clinical outcomes were a consequence of changes in
practice.ortality and Nonfatal Outcomes by Calendar Period Among Patients
ting for at Least 5 Years in the RIETE Registry
Risk-Adjusted Rates (%)* Adjusted Rate
Ratio Per Period
(95% CI)†
p Value
for Trend†2001–2005 2006–2009 2010–2013
6.7 6.1 4.8 0.84 (0.72–0.98) 0.03
2.9 2.7 1.9 0.82 (0.67–1.0) 0.05
3.4 2.7 1.8 0.74 (0.60–0.91) <0.01
2.2 1.9 1.2 0.74 (0.59–0.93) <0.01
1.1 0.6 0.6 0.70 (0.56–0.87) <0.01
4.0 2.6 2.8 0.84 (0.72–0.96) 0.01
cause mortality, PE-related mortality, and nonfatal complications for each calendar
e overall cohort. Rates were adjusted for temporal changes in patient and hospital
for all model covariates). †Adjusted risk ratios and p values for trend were determined
lendar period as a continuous variable.
atizado de la Enfermedad TromboEmbólica; other abbreviations as in Tables 2 and 3.Few studies have addressed the temporal trends of
various aspects related to the care and outcomes of
patients with PE, such as duration of hospital stay,
therapy, and all-cause and PE-related mortality
(22,23). Previous studies have suggested that the
length of stay and the case-fatality rate of PE have not
changed over time (24–26). Alternatively, we found
substantial improvements in the length of hospital
stay, similar to other studies for patients admitted
with cardiovascular diseases other than PE (e.g., heart
failure) (27). Although some health systems have
provided an incentive for shortening length of
stay, the generalized use of anticoagulant agents
(e.g., low-molecular-weight heparin) that combine
greater convenience with similar or better efﬁcacy
and safety proﬁles compared with the previous
standard approaches (e.g. unfractionated heparin)
might explain this ﬁnding.
In our study, the increased use of more effective
therapies and interventions, including low-molecular-
weight heparins, direct oral anticoagulants, throm-
bolysis, and surgical embolectomy, was accompanied
by a statistically signiﬁcant decrease in the rates of
death, nonfatal recurrences, and nonfatal major
bleeding. Although this study does not imply causal-
ity, the decrease of PE-speciﬁc (i.e., recurrent VTE) and
treatment-related (i.e., bleeding) complications and
PERSPECTIVES
COMPETENCY IN PRACTICE-BASED LEARNING:
Improvements in the initial treatment of PE have been accom-
panied by reductions in length of hospital stay, as well as
short-term all-cause and PE-speciﬁc mortality.
TRANSLATIONAL OUTLOOK: Future studies should evaluate
the relative effect of pharmacological therapy and catheter-
directed interventions on clinical outcomes across a variety of
treatment settings over a long period of time.
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169PE-related mortality may reﬂect the more widespread
use of therapies shown in trials and meta-analyses to
lower the risk of recurrent VTE and bleeding compli-
cations (28). Treatment pattern changes likely played a
larger role in affecting outcomes than any changes in
patients’ baseline characteristics.
Several issues merit further critical review and dis-
cussion. First, the decreases in all-cause and PE-
associated mortality may simply reﬂect a decrease in
baseline riskover time.However,we found little evidence
that this occurred. Although patients in our study were
younger by approximately 2 years at the end of the study
period than those at the beginning, with less immobili-
zation and a lower heart rate, they also had higher rates of
cancer, chronic lung disease, chronic heart failure, hypo-
tension, and laboratory abnormalities (e.g., renal failure,
anemia). Moreover, the study showed consistent results
even after adjustment for temporal changes in patient
characteristics over time, including age. Second,
increasing use of the CT scan for PE diagnosis could have
introduced selection bias into the registry over time (29).
The observed decrease in length of stay may reﬂect an
increase in the detection of minor PE, which could ac-
count for the lower 30-day mortality. The observed tem-
poral increase in severity markers (e.g., mean sPESI)
suggests otherwise. Furthermore, mortality trends did
not differ by diagnostic test (CT vs. V/Q scan). Finally, the
analyses did not support that the study ﬁndingswere due
to enrollment of better-performing hospitals over time,
because we found similar results when we restricted our
analyses to hospitals that participated in the RIETE reg-
istry for 5 years or longer.
STUDY LIMITATIONS. First, although data in the
RIETE registry allowed us to adjust for a number of key
variables, the possibility of residual confounding still
remains. Second, we did not have complete informa-
tion on speciﬁc hospital-based risk-stratiﬁcation pro-
tocols (e.g., troponin, echocardiogram), treatment
details (e.g., international normalized ratio control,
concomitant medications), and quality-improvement
initiatives at hospitals (e.g., adherence to guidelines)
to better understand the reasons for decreased mor-
tality. These are often difﬁcult to document accu-
rately, and further studies are required to examine the
role of these factors in explaining the temporal
decrease in mortality. Third, the low mortality rate for
patients diagnosed with PE might suggest that RIETE
enrolled a less ill population. However, the study
cohort showed a 30-daymortality rate of 5.9% that was
similar to the 5.4% mortality rate in the EMPEROR
(Emergency Medicine Pulmonary Embolism in the
Real World Registry) registry (30). Furthermore, our
data are consistent with the 2007 National ED Survey,which reported a 3.3% in-hospital mortality rate for
121,026 emergency department patients diagnosed
with PE (31). Another limitation of the study was
the lack of data evaluating catheter-directed
interventions, and we could not assess the effect
of these therapies on clinical outcomes. Finally,
although we found that improved survival trends were
independent of the duration of hospital participation
in the RIETE registry, our study cohort was probably
composed of hospitals that were enthusiastic about
evidence-based management of PE, and the results
may not be fully generalizable elsewhere. However,
the RIETE registry is the only large-scale, multina-
tional, observational study of the spectrum of patients
diagnosed with a PE with continuous recruitment
of patients for more than 10 years, and it offers a
unique opportunity to look at a large number of
patients in various treatment settings over a long
period of time.
CONCLUSIONS
Contemporary multinational observational data from
the RIETE registry showed signiﬁcant temporal
changes in the management of patients with PE that
were consistent with trial evidence and national and
international guidelines. This study population
demonstrated signiﬁcant reductions in all-cause and
PE-related mortality over time.
ACKNOWLEDGMENTS The authors thank the RIETE
Registry Coordinating Center, S & H Medical Science
Service, for their quality control data, logistic, and
administrative support.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
David Jiménez, Respiratory Department and Medi-
cine Department, Ramón y Cajal Hospital, IRYCIS and
Alcalá de Henares University, Colmenar Road Km.
9,100, 28034 Madrid, Spain. E-mail: djimenez.hrc@
gmail.com.
Jiménez et al. J A C C V O L . 6 7 , N O . 2 , 2 0 1 6
Acute PE Management J A N U A R Y 1 9 , 2 0 1 6 : 1 6 2 – 7 0
170RE F E RENCE S1. Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary
embolism, part I: epidemiology, risk factors and risk
stratiﬁcation, pathophysiology, clinical presenta-
tion, diagnosis and nonthrombotic pulmonary em-
bolism. Exp Clin Cardiol 2013;18:129–38.
2. Heit JA. The epidemiology of venous thrombo-
embolism in the community. Arterioscler Thromb
Vasc Biol 2008;28:370–2.
3. Simonneau G, Sors H, Charbonnier B, et al.
A comparison of low-molecular-weight heparin
with unfractionated heparin for acute pulmonary
embolism. N Engl J Med 1997;337:663–9.
4. The Columbus Investigators. Low-molecular-
weight heparin in the treatment of patients with
venous thromboembolism. N Engl J Med 1997;
337:657–62.
5. The Matisse Investigators. Subcutaneous fon-
daparinux versus intravenous unfractionated hep-
arin in the initial treatment of pulmonary
embolism. N Engl J Med 2003;349:1695–702
[Erratum in N Engl J Med 2004;350:423].
6. Hull RD, Raskob GE, Brant RF, et al. Low-
molecular-weight heparin vs heparin in the treat-
ment of patients with pulmonary embolism. Arch
Intern Med 2000;160:229–36.
7. Kearon C, Akl EA, Comerota AJ, et al. Anti-
thrombotic therapy for VTE disease: anti-
thrombotic therapy and prevention of thrombosis,
9th ed: American College of Chest Physicians.
Evidence-Based Clinical Practice Guidelines. Chest
2012;141:419S–94S.
8. Konstantinides SV, Torbicki A, Agnelli G, et al.
2014 ESC guidelines on the diagnosis and man-
agement of acute pulmonary embolism: the Task
Force for the Diagnosis and Management of Acute
Pulmonary Embolism of the European Society of
Cardiology (ESC). Eur Heart J 2014;35:3033–73.
9. Witty LA, Krichman A, Tapson VF. Thrombolytic
therapy for venous thromboembolism. Utilization
by practicing pulmonologists. Arch Intern Med
1994;154:1601–4.
10. Egermayer P, Town GI. Compliance with
guidelines for the investigation and manage-
ment of patients with suspected pulmonary em-
bolism at Christchurch Hospital. N Z Med J 1998;
111:70–3.
11. Laporte S, Mismetti P, Décousus H, et al.
Clinical predictors for fatal pulmonary embolism in
15,520 patients with venous thromboembolism:
ﬁndings from the RIETE registry. Circulation 2008;
117:1711–6.12. Muriel A, Jiménez D, Aujesky D, et al. Survival
effects of inferior vena cava ﬁlter in patients with
acute symptomatic venous thromboembolism and
a signiﬁcant bleeding risk. J Am Coll Cardiol 2014;
63:1675–83.
13. Monreal M, Kakkar AK, Caprini JA, et al. The
outcome after treatment of venous thromboem-
bolism is different in surgical and acutely ill
medical patients. Findings from the RIETE registry.
J Thromb Haemost 2004;2:1892–8.
14. Riera-Mestre, Jiménez D, Muriel A, et al.
Thrombolytic therapy and outcome of patients
with an acute symptomatic pulmonary embolism.
J Thromb Haemost 2012;10:751–9.
15. Nieto JA, Tuesta AD, Marchena PJ, et al. Clin-
ical outcome of patients with venous thrombo-
embolism and recent major bleeding: ﬁndings of a
prospective registry (RIETE). J Thromb Haemost
2005;3:703–9.
16. Remy-Jardin M, Remy J, Wattinne L, Giraud F.
Central pulmonary thromboembolism: diagnosis
with spiral volumetric CT with the single-breath-
hold-technique-comparison with pulmonary angi-
ography. Radiology 1992;185:381–7.
17. PIOPED Investigators. Value of ventilation/
perfusion scan in acute pulmonary embolism:
results of the prospective investigation of the
pulmonary embolism diagnosis (PIOPED). JAMA
1990;263:2753–9.
18. Kearon C, Ginsberg JS, Hirsh J. The role of
venous ultrasonography in the diagnosis of sus-
pected deep venous thrombosis and pulmonary
embolism. Ann Intern Med 1998;129:1044–9.
19. Krumholz HM, Keenan PS, Brush JE Jr., et al.
Standards for measures used for public reporting
of efﬁciency in health care: a scientiﬁc statement
from the American Heart Association Interdisci-
plinary Council on Quality of Care and Out-
comes Research and the American College of
Cardiology Foundation. Circulation 2008;118:
1885–93.
20. Raghunathan T, Solenberger P, Van Hoeyk J.
IVEware: Imputation and Variance Estimation
Software—User’s Guide. Ann Arbor, MI: University
of Michigan Survey Research Center, Institute for
Social Research, 2002.
21. Jiménez D, Aujesky D, Moores L, et al. Simpli-
ﬁcation of the pulmonary embolism severity index
for prognostication in patients with acute symp-
tomatic pulmonary embolism. Arch Intern Med
2010;170:1383–9.22. Park B, Messina L, Dargon P, et al. Recent
trends in clinical outcomes and resource utilization
for pulmonary embolism in the United States.
Chest 2009;136:983–90.
23. Shiraev TP, Omari A, Rushworth RL. Trends in
pulmonary embolism morbidity and mortality in
Australia. Thromb Res 2013;132:19–25.
24. Anderson FA Jr.,WheelerHB, GoldbergRJ, et al.
A population-based perspective of the hospital
incidence and case-fatality rates of deep vein
thrombosis andpulmonaryembolism: theWorcester
DVT study. Arch Intern Med 1991;151:933–8.
25. Lilienfeld DE, Godbold JH, Burke GL, et al.
Hospitalization and case fatality for pulmonary
embolism in the Twin Cities: 1979–1984. Am Heart
J 1990;120:392–5.
26. Stein PD, Kayali F, Olson RE. Estimated case-
fatality rate of pulmonary embolism, 1979 to
1998. Am J Cardiol 2004;93:1197–9.
27. Bueno H, Ross JS, Wang Y, et al. Trends in
length of stay and short-term outcomes among
Medicare patients hospitalized for heart failure,
1993–2006. JAMA 2010;303:2141–7.
28. Castellucci LA, Cameron C, Le Gal G, et al.
Clinical and safety outcomes associated with
treatment of acute venous thromboembolism: a
systematic review and meta-analysis. JAMA 2014;
312:1122–35.
29. Wiener RS, Schwartz LM, Woloshin S. Time
trends in pulmonary embolism in the United
States: evidence of overdiagnosis. Arch Intern Med
2011;171:831–7.
30. Pollack CV, Schreiber D, Goldhaber SZ, et al.
Clinical characteristics, management, and out-
comes of patients diagnosed with acute pulmo-
nary embolism in the emergency department.
J Am Coll Cardiol 2011;57:700–6.
31. Healthcare Cost and Utilization Project
(HCUP). National (Nationwide) Inpatient Sample
(NIS). Available at: http://www.hcup-us.ahrq.gov/
nisoverview.jsp. Accessed December 1, 2010.KEY WORDS heparin, length of stay,
outcomes, prognosis, surgical embolectomy,
survival, thrombolysisAPPENDIX For a list of RIETE Registry
members, please see the online version of this
article.
